Ruta D. Rao, MD, discusses a prospective sub-study of the PARTNER trial evaluating the effect of ctDNA status on distant recurrence in early TNBC.
Ruta D. Rao, MD
Advertisement
Ruta D. Rao, MD, a professor in the Department of Internal Medicine in the Division of Hematology, Oncology and Cell Therapy, director of the Coleman Foundation Comprehensive Breast Cancer Clinic, and medical director of the RUSH University Cancer Center
Articles by Ruta D. Rao, MD
Ruta D. Rao, MD, discusses how the updated National Comprehensive Cancer Network guidelines have influenced treatment selection for patients with HER2-positive breast cancer.
Ruta D. Rao, MD, an associate professor at Rush University Medical Center, discusses therapy de-escalation for patients with early-stage hormone receptor (HR)-positive, HER2-negative breast cancer.
Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5